Additionally, rapid, substantial and sustained statistically significant reductions in 17-OHP, a confirmatory secondary biomarker of disease control, were achieved across doses. Treatment with ...
Zacks.com on MSN23h
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy DesignationDenali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback